Category: Generative AI & LLMs
Clinical study reports, protocols, and summary documents are assembled by hand from source tables and prior documents — and writing capacity, not data availability, often sets the submission timeline.
The documents a submission depends on — clinical study reports, protocols, patient narratives, summary modules — are largely assembled from material that already exists: statistical outputs, prior studies, standard language, and source data. Yet each one is drafted by hand, reviewed in long cycles, and rewritten across versions, so medical-writing capacity becomes the constraint on how fast a program moves. Generative AI writing tools draft these documents from the underlying sources, so writers start from a grounded draft instead of a blank page.
Regulated documents follow strong conventions: a clinical study report has a defined structure, draws its numbers from the statistical outputs, and reuses substantial standard language from protocol and prior documents. Generative writing tools exploit exactly that regularity — they assemble a first draft from the source tables, the protocol, and an organization's approved templates and prior submissions, keeping each generated statement tied to the source it came from. The writer's job shifts from transcribing numbers into sentences toward reviewing, interpreting, and shaping the scientific story. What the tools do not replace is authorship. The medical writer and the clinical team remain accountable for every statement in the final document — the interpretation of results, the framing of safety findings, the decisions about emphasis and omission. Tools built for this domain make review efficient by linking generated text back to its sources, so a reviewer can verify a claim instead of taking it on faith.
Source grounding is the deciding property: every number and factual claim in a generated draft should be traceable to a specific table, dataset, or approved document, and the tool should make that link visible in review. Probe what happens when a source is missing — a credible tool leaves an explicit gap for the writer rather than filling it with plausible text. Then test on your own material: give the tool a completed study's outputs and compare its draft against the report your writers actually produced, scoring both accuracy and how much of the draft survived expert review. Workflow fit matters as much as draft quality. The tool has to work within your document-management and review process — versioning, tracked changes, reviewer sign-offs, and the audit trail your quality system expects — rather than producing text in a parallel system that someone re-imports by hand.
Most teams pilot on a document type that is high-volume and highly structured — patient narratives and clinical study report sections are common choices — using a completed study where the human-written version already exists as ground truth. Writers score the generated draft line by line: what was accurate, what was wrong, what was missing, and how long the review took compared with drafting from scratch. That produces a defensible read on whether the tool adds throughput on your documents, with your standards, before it touches a live submission timeline.
It can draft substantial parts of one — assembling structured sections from the statistical outputs, protocol, and approved templates, with each statement tied to its source. The medical writer and clinical team review every statement and remain accountable for the final document; the tool changes where writing time goes, not who is responsible for the content.
By requiring traceability. Tools built for regulated writing link each generated claim back to the table or document it came from, so reviewers verify rather than trust. In evaluation, run the tool on a completed study and compare its draft against the report your team actually wrote — differences show up quickly against ground truth.
Regulators evaluate the document and the process that controls it, and the sponsor remains fully accountable for content regardless of how a draft was produced. That is why review rigor, traceability, and your existing quality process matter more than the drafting method — the same standards apply whether the first draft came from a person or a tool.
High-volume, highly structured documents where sources are well defined — patient narratives and standard report sections are typical starting points. Documents dominated by novel scientific argument benefit less from generation and more from the assembly and consistency-checking capabilities around them.
The U.S. FDA renewed and expanded its long-standing collaboration licensing Certara's Simcyp physiologically-based pharmacokinetic (PBPK) simulator, with hundreds of agency licenses used to inform regulatory review of drug dosing and interactions.
Vendor: Certara · press release (Certara (GlobeNewswire)) · 2021-12-21 — Partner: U.S. FDA
Yseop announced a strategic investment and a milestone of clinical trials supported by its generative AI for regulatory and medical writing.
Vendor: Yseop · press release (Yseop (GlobeNewswire)) · 2023-12-07